Searchable abstracts of presentations at key conferences in endocrinology

ea0011p237 | Cytokines and growth factors | ECE2006

Growth hormone receptor extracellular domain linked to glycophosphatidyl inositol (GHR-GPI); a potential growth hormone receptor antagonist

Bowles CE , Wilkinson I , Gavalas N , Watson P , Watts D , Ross R

Introduction: The growth hormone receptor (GHR) consists of 620 residues and belongs to the class I cytokine receptor family. It is a single membrane spanning protein that binds its ligand, GH, via the extracellular domain. GH binding to GHR induces a conformational change in the preformed receptor dimer, which leads to intracellular signalling. Correct functional dimerisation of two GHR molecules is essential for GH signalling. We have previously shown that membrane bound tru...

ea0026oc2.5 | Neuroendocrinology | ECE2011

Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinemia

Trifiro G , Mokhles M , Dieleman J , van Soest E , Mazzaglia G , Herings R , de Luise C , Ross D , Brusselle G , Colao A , Haverkamp W , Schade R , van Camp G , Zanettini R , Sturkenboom M

Background: There is growing evidence that ergot dopamine agonists (DA) may induce cardiac valve regurgitation (CVR) in persons with Parkinson’s disease (PD). It is unclear whether the CVR risk is increased with ergot-DA use in persons with hyperprolactinemia, in whom the dose is much lower.Objective: To assess the association between ergot and non-ergot DAs and CVR in patients with hyperprolactinemia and PD.Methods: Nested ca...